Tremfya vs Omvoh for Crohn's Disease: Key Differences

Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, each newly approved for the indication. Tremfya gained Crohn's approval in March 2025 based on GALAXI-2 and GALAXI-3, with the GRAVITI trial supporting a fully subcutaneous induction option. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh administration flexibility and active-comparator trial design. This guide walks through the tremfya vs omvoh crohn's comparison.

Same Class, Two Molecules

Tremfya (guselkumab) and Omvoh (mirikizumab) both bind the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 drives Th17 inflammation central to Crohn's disease pathology. The guselkumab vs mirikizumab comparison is a within-class decision, so the structural mechanism is shared, but the molecules differ in affinity, half-life, and the clinical programs that support each.

Trial Evidence: GALAXI and GRAVITI vs VIVID-1

Tremfya's Crohn's approval rests on GALAXI-2 and GALAXI-3, two pivotal phase 3 trials that compared guselkumab with placebo and with ustekinumab (Stelara). Tremfya demonstrated statistical superiority over Stelara on endoscopic response at week 48 in pooled analyses. GRAVITI separately evaluated fully subcutaneous induction for guselkumab in Crohn's, demonstrating that patients could skip IV induction entirely and still achieve meaningful response. Omvoh's Crohn's approval rests on VIVID-1, a three-arm trial comparing mirikizumab with placebo and with ustekinumab. VIVID-1 showed mirikizumab superior to placebo on co-primary endpoints of clinical remission and endoscopic response, with a key secondary endpoint establishing non-inferiority to Stelara. The GRAVITI vs VIVID-1 design difference is informative because GRAVITI uniquely supports SC-only induction, while VIVID-1 provides direct non-inferiority data against Stelara.

Efficacy Comparison

No head-to-head trial has directly compared Tremfya with Omvoh in Crohn's. Both drugs showed superiority over placebo in their respective pivotal programs. Both had Stelara arms, which allows cross-trial comparison as a proxy, though this is less rigorous than a direct head-to-head. GALAXI showed Tremfya superior to Stelara on endoscopic response. VIVID-1 showed Omvoh non-inferior to Stelara on its endpoints. For tremfya vs omvoh effectiveness, these data suggest both drugs are meaningful options with comparable efficacy, and choice often defaults to administration and dosing.

Onset of Action

Both drugs produce clinically meaningful Crohn's response by week 12. Tremfya's GALAXI program used a week 12 endoscopic response endpoint. Omvoh's VIVID-1 used week 12 clinical remission and endoscopic response endpoints. For patients in active flare who need rapid improvement, the two drugs are comparable in practice.

Administration and Dosing

Tremfya for Crohn's offers a distinctive dual induction pathway. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) per the GALAXI and GRAVITI programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. Omvoh for Crohn's uses IV induction at 900 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 300 mg every 4 weeks (administered as two 150 mg injections), per Lilly's prescribing information. For Crohn's patients who want to avoid infusion center visits entirely, Tremfya's SC-only induction option is a meaningful practical advantage. For maintenance, Tremfya's every-8-week SC cadence is less frequent than Omvoh's every-4-week SC dosing.

Safety Profiles

Both drugs have favorable safety profiles consistent with IL-23 p19 class effects. Long-term data from each drug's other indications (psoriasis and psoriatic arthritis for Tremfya, UC for Omvoh) supports low rates of serious infection and malignancy. For tremfya vs omvoh side effects, common adverse events on both drugs include upper respiratory infections, injection site reactions, and headache. Neither drug has a black-box warning for lymphoma or other class-level serious adverse events seen with anti-TNFs. TB and hepatitis B screening is recommended before starting either drug.

Injection Experience

Tremfya's Crohn's maintenance (100 mg every 8 weeks) uses a standard prefilled syringe or One-Press autoinjector. Omvoh's Crohn's maintenance (300 mg every 4 weeks, delivered as two 150 mg injections) requires two separate injections per dose. Some patients prefer the single-injection convenience of Tremfya, while others find Omvoh's split injection manageable given the more frequent schedule.

Cost and Access

Both Tremfya and Omvoh are branded biologics without biosimilar competition. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in Crohn's. Manufacturer copay assistance programs exist for commercially insured patients on both drugs. Since both drugs are recent additions to the Crohn's market, some insurance plans may have evolving formulary status for these indications.

Choosing With Your GI

For a Crohn's patient deciding between Tremfya and Omvoh, Tremfya tends to win on induction flexibility (SC or IV via GALAXI and GRAVITI), less frequent SC maintenance (every 8 weeks), and the single-injection device. Omvoh tends to win on active comparator trial design against Stelara (VIVID-1) and the simplicity of a unified IV induction pathway. Ask your GI which drug they have the most experience with, how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.